Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: james who wrote (2877)	11/19/1997 1:11:00 AM
From: Pseudo Biologist	Read Replies (1) of 6136

james, re. the "T-cell treatment" See the full gory details in the PNAS article at pnas.org This would an ex-vivo gene therapy approach. The idea is to take CD8+ T-cells out from the patient and modify them ex-vivo by making them express a universal receptor gene (UR). This UR, for the case of AIDS, could be CD4 itself. The idea is that UR-modified T-cells would then become able of finding HIV-infected cells and kill them. The procedure is in phase I or II trials; look for press releases out of Cell Genesys (CEGE) for the clinical details. This approach would not replace current triple-drug therapy, but rather it may complement it. On Agouron's pipeline; off the top of my head and without going back in the thread I can think of one cancer TS inhibitor in phase III trials; an interesting matrix metalloproteinase inhbitor (cf. British Bio) also for cancer, and a rhinovirus protease inhbitor. They also acquired Alanex recently, an interesting combi-chem company. Check agouron.com for a full list and further links to details on each compound. PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next